Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Duragesic/h+ Scotch Duct Tape · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M) |
| 2 | EXPERIMENTAL | Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M) |
| 3 | EXPERIMENTAL | Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M) |
| 4 | EXPERIMENTAL | Duragesic 25 mcg/h + Scotch Duct Tape (3M) |
| 5 | EXPERIMENTAL | Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M) |
| 6 | EXPERIMENTAL | Duragesic 25 mcg/h + Microfoam Tape (3M) |
| Name | Type | Description |
|---|---|---|
| Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M) | DRUG | single application |
| Duragesic 25 mcg/h + Scotch Duct Tape (3M) | DRUG | single application |
| Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M) | DRUG | single application |
| Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M) | DRUG | single application |
| Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M) | DRUG | single application |
| Duragesic 25 mcg/h + Microfoam Tape (3M) | DRUG | single application |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (beta-HCG) pregnancy tests performed within 21 days prior to the start of the study and on the ev...
Duragesic/h+ Scotch Duct Tape is a small molecule drug being developed by Viatris Inc. (VTRS). It is currently in Phase 1 clinical development for use in healthy volunteers. The drug is being studied in a bioequivalence and wear study of the Mylan Fentanyl Transdermal System.
Duragesic/h+ Scotch Duct Tape is being studied for use in healthy volunteers. The ongoing clinical trial is a bioequivalence and wear study of the Mylan Fentanyl Transdermal System 25 µg/h. It is an investigational drug still in clinical development and has not been approved for any indication.
Duragesic/h+ Scotch Duct Tape is being developed by Viatris Inc., which trades under the ticker VTRS. The company is conducting a Phase 1 clinical trial to evaluate the drug in healthy volunteers.
Duragesic/h+ Scotch Duct Tape is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and there are no active trials currently.
Duragesic/h+ Scotch Duct Tape has one completed clinical trial, NCT00650117, titled "Bioequivalence and Wear Study of Mylan Fentanyl Transdermal System 25 µg/h and Mylan Fentanyl Transdermal System." This Phase 1 study enrolled 12 healthy volunteers in the United States and was controlled and randomized.